logo
Opinion - Why is the anti-abortion movement scared of telemedicine?

Opinion - Why is the anti-abortion movement scared of telemedicine?

Yahoo18-02-2025

You need medical care, but the earliest available appointment isn't for weeks. Even if you could wait, you'd still have to take time off work, find childcare and somehow get to a clinic that's an hour away. America has some of the best medical expertise in the world, but actually accessing that care is like trying to solve a Rubik's cube blindfolded.
The most radical change the pandemic brought to the U.S. health care system was the near-universal embrace of telemedicine to deliver virtual care. Telemedicine eases the strain on the system by using technology to enable a doctor's visit without the commute. This positive effect is especially apparent in reproductive health and the expansion of abortion access.
And yet abortion care via telemedicine is under attack as the administration responsible for the fall of Roe v. Wade returns to power and as cases are litigated in conservative states across the country seeking to ban medication abortion altogether.
Anti-abortion extremists are threatened by telemedicine because it allows you, the patient, to get the care you need. Medication abortion, which involves taking two FDA-approved pills (mifepristone and misoprostol) to end an early pregnancy, now accounts for 63 percent of abortions in the U.S. But despite its safety and efficacy, conservative lawmakers are escalating efforts to restrict access to these medications.
Today one in five abortion-seekers choose to use telemedicine to receive care. As the CEO of Hey Jane, a virtual abortion clinic that's helped over 75,000 patients access care, I can tell you firsthand: telemedicine isn't just a pandemic-era stopgap. It is the key to enabling access in a broken health care system. This is why we must protect it from the latest attacks by anti-abortion extremists.
It's crucial we protect telemedicine as a way to access prescription medicine, including medication abortion. Telehealth is not just more convenient — it's transforming how health care works at a fundamental level. Since launching, my company has seen an overwhelming demand for medication abortion via telemedicine, and what we've learned has implications for the entire health care system.
That whole 'nothing beats in-person' argument? Our data shows that 98 percent of patients actually prefer asynchronous communications, meaning they want to manage their health care on their own time, through messages and updates, rather than scheduling their lives around getting to a doctor's office. Privacy is another key factor, with nearly half of our patients indicating privacy was what was most important to them during treatment. They want care that is discreet, fast and built around their lives.
For many patients, accessing medication abortion on their own terms is life-changing — especially in states where in-person clinics are few and far between. Take Virginia, where 93 percent of counties don't have in-person abortion clinics, and those that do are inundated with patients from surrounding states, which have some of the most restrictive abortion laws in the country. Even in states where abortion is legal and available, it may not actually be accessible.
Virtual abortion clinics aren't just an alternative. They are often the only realistic option for patients who can't take a day off work or drive hundreds of miles to the nearest clinic.
Telemedicine is democratizing health care in ways we've never seen before. With lower overhead costs, virtual clinics can offer more affordable care while removing the often prohibitive costs of transportation, child care and lost wages for the patient.
Skeptics said Americans wouldn't trust telemedicine for important health-care decisions, that the technology wasn't ready, that patients would always prefer in-person care. They were wrong on all counts. Now we must fight against conservative extremists who are trying to cherry-pick what is accessible via telemedicine as a way to police the bodies of pregnant women.
The future of the industry is about using technology to make health care work for everyone. The fight over telemedicine is, at its core, a fight over access to medication abortion. Conservative extremists know that if they can cut off access to these pills, they can effectively eliminate the abortion method of choice for the majority of Americans — in every state. We cannot let that happen.
The tools are here. The technology works. The patients want it. Elected officials must step up and protect access to this essential health care.
Kiki Freedman is the cofounder and CEO of Hey Jane.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Felycin®-CA1 (sirolimus delayed-release tablets) Redefines Feline Cardiac Care
Felycin®-CA1 (sirolimus delayed-release tablets) Redefines Feline Cardiac Care

Associated Press

time30 minutes ago

  • Associated Press

Felycin®-CA1 (sirolimus delayed-release tablets) Redefines Feline Cardiac Care

First-in-class oral management option for hypertrophic cardiomyopathy earns FDA conditional approval, changing the landscape of feline medicine PENSACOLA, Fla., June 12, 2025 /PRNewswire/ -- Pegasus Laboratories/PRN Pharmacal has announced the addition of a new FDA conditionally approved drug, Felycin®-CA1 (sirolimus delayed-release tablets), to their portfolio. This first-in-class therapy is designed to manage ventricular hypertrophy in cats with subclinical hypertrophic cardiomyopathy (HCM), representing a major milestone in feline medicine and offering new hope to owners of cats living with this progressive and often fatal disease. HCM is a heart condition which causes the muscular walls of a cat's heart to become abnormally thick, reducing the heart's ability to pump blood efficiently. This can lead to heart failure and other complications, including sudden death. Many cats with HCM remain subclinical for years, while others may develop symptoms of congestive heart failure. While the exact cause of the disease is not fully understood, HCM is more common in certain breeds, including British Shorthair, Chartreux, Maine Coon, Persian, Ragdoll, and Sphynx cats. Researchers have also identified mutations in various cardiac genes causing HCM in several of these breeds. 'Felycin-CA1 signals a turning point in feline medicine by providing veterinarians a much-needed option to help slow the progression of HCM beyond just managing the disease,' said Dr. Heather Davis, DVM, PhD, DACVS-LA, Director of Clinical Affairs and Veterinary Services at Pegasus Laboratories. 'It is a major step forward for cats and the people who care for them. For the first time, we're changing the conversation around what's possible in feline heart care.' FDA conditional approval of Felycin®-CA1 follows results from a multi-center study demonstrating its ability to improve key cardiac outcomes, while also proving its ease of use in everyday veterinary practices. 'Veterinarians have long-needed options beyond palliative care when it comes to feline HCM,' said Dr. Joshua Stern, DVM, PhD, DACVIM. 'With Felycin-CA1, we can offer a therapy that has been shown in our initial clinical trial to stop progressive heart muscle thickening, slowing disease progression. We believe this management option marks the beginning of a new chapter where innovation in feline therapeutics becomes the rule, not the exception.' Felycin®-CA1 is slated to be available beginning August 2025, in 0.4 mg, 1.2 mg, and 2.4 mg tablet strengths by prescription from a licensed veterinarian. Cats should be screened for pre-existing liver disease before starting the medication, and it should not be used in cats with pre-existing liver disease or diabetes mellitus. About Pegasus Laboratories Pegasus Laboratories, Inc., based in Pensacola Florida, is a pharmaceutical development and manufacturing organization focused on innovative products to treat chronic conditions in cats, dogs, and horses. Our products go to market under the PRN® Pharmacal brand. We also serve as a contract manufacturer for the Animal Health industry. We were founded in 1985 and acquired by PBI-Gordon Companies, Inc. in 1999. View original content to download multimedia: SOURCE Pegasus/PRN Pharmacal

Newly approved antibody could offer another option for protecting infants from RSV, a common infection that can be deadly
Newly approved antibody could offer another option for protecting infants from RSV, a common infection that can be deadly

CNN

time38 minutes ago

  • CNN

Newly approved antibody could offer another option for protecting infants from RSV, a common infection that can be deadly

The United States could soon have another tool in the fight against respiratory syncytial virus, an illness that's the No. 1 cause of hospitalization in infants. The US Food and Drug Administration has approved a new monoclonal antibody to help prevent infection, according to an announcement late Monday from drugmaker Merck. Enflonsia is designed to be given in a single 105-milligram shot to protect newborns and infants from mild, moderate or severe RSV through all five months of their first virus season, which typically starts in the fall and goes through the next spring. Study materials that Merck submitted to the FDA for its approval showed that the antibody had a similar safety profile as a placebo. The most common adverse reactions from Enflonsia were mild and included injection-site swelling and a rash in a small number of infants. In a mid- to late-stage trial, Enflonsia reduced RSV-associated hospitalizations in infants more than 84% compared with a placebo. RSV can sometimes turn into serious lower respiratory infections like pneumonia, but the shot also reduced lower respiratory infections that needed medical attention by more than 60% compared with a placebo. 'Enflonsia provides an important new preventive option to help protect healthy and at-risk infants born during or entering their first RSV season,' Dr. Dean Y. Li, president of Merck Research Laboratories, said in a news release. 'We are committed to ensuring availability of Enflonsia in the US before the start of the upcoming RSV season to help reduce the significant burden of this widespread seasonal infection on families and health care systems.' Merck says it hopes Enflonsia will be available before the start of the 2025-26 respiratory virus season. First, it needs to be recommended by the US Centers for Disease Control and Prevention, and that means going in front of the agency's Advisory Committee on Immunization Practices. It's on the agenda for the panel's meeting this month, but US Health and Human Services Secretary Robert F. Kennedy removed all the members of that committee Monday. He says he will appoint new ones, but it's unclear how long that process will take. Doctors say another tool to prevent RSV cannot come soon enough. RSV is ubiquitous, one of the most common causes of childhood illness. Most kids will catch this highly contagious respiratory virus at some point before they turn 2, according to the CDC. For many healthy adults and older kids, RSV causes a mild illness like a cold. Typically, symptoms can be managed at home, and they often go away on their own. But for infants and the elderly, it can be a different story. Very young children's immune systems are just starting to learn how to fight infections, and infants have tiny airways. RSV inflames those airways, making it difficult to breathe, and can turn into a serious lower respiratory illness like bronchiolitis or pneumonia. Some of these RSV infections can be deadly. Two to three percent of infants under 6 months are hospitalized with RSV in the US every year, according to the CDC. Among children younger than 5, about 58,000 to 80,000 are hospitalized due to RSV. There's no specific medicine to treat RSV. Doctors can give an infant supportive care and oxygen, and then they essentially wait until their oxygen levels get back to normal, said Dr. Amy Edwards, director of pediatric infection control at UH Rainbow Babies and Children's Hospital in Cleveland. 'I hate RSV,' said Edwards, who was not connected with the Merck trial. 'Just to watch them struggle to breathe, and then they get scared, and then they cry, which of course makes the breathing worse, and their little lips turn blue. It's just so hard to watch.' Enflonsia joins a handful of other tools recently made available to protect babies from, although the FDA put RSV vaccine trials involving infants and young children ages 2 to 5 on hold last year after some developed severe illness. To prevent RSV in infants, the CDC currently recommends an RSV antibody made by Sanofi and AstraZeneca, called Beyfortus, which was approved in 2023. It was in short supply during that year's RSV season, although Edwards said supply started to catch up with demand in her health care system last season, and the company pledged to produce more. The other option to protect an infant is a vaccine that a person can get during pregnancy. Together, Beyfortus and the vaccine have made a difference. A CDC study published in March found that RSV-associated hospitalization rates among infants up to 7 months during 2024-25 season were lower than in seasons when those things weren't available. Edwards just hopes people will get protection for their infants. 'Every RSV season fills us to the gills,' she said. 'This should theoretically empty us out, if we have good uptake.' Correction: A previous version of this story incorrectly described the newly approved monoclonal antibody as a therapy.

Epiminder Announces Publication of Landmark Clinical Trial Confirming Safety and Efficacy of the Minder® System
Epiminder Announces Publication of Landmark Clinical Trial Confirming Safety and Efficacy of the Minder® System

Business Wire

timean hour ago

  • Business Wire

Epiminder Announces Publication of Landmark Clinical Trial Confirming Safety and Efficacy of the Minder® System

MELBOURNE, Australia & DALLAS--(BUSINESS WIRE)-- Epiminder, a pioneer in implantable continuous EEG monitoring (iCEM™), today announced the publication of results from its landmark UMPIRE (sUb-scalp Monitoring ePileptic seIzuREs) clinical trial in Epilepsia validating the safety and efficacy of its iCEM. The study, conducted across leading Australian hospitals, demonstrated Minder's ability to capture high-quality EEG data for extended periods that are comparable to current standard of care scalp-based EEG monitors. The Minder system is a designated Breakthrough Device and has recently been granted clearance for marketing in the United States by the FDA. A world record five-year continuous EEG recording has recently been reported by Epiminder using the system. 'The UMPIRE results exceeded our expectations, proving that continuous EEG monitoring over years—not just days—is not only possible but transformative for epilepsy management,' said Professor Mark Cook, Epiminder's Founder and Chief Medical Officer. Key Highlights of UMPIRE Clinical Trial: The Minder system was found to be safe, with no device or procedure related Serious Adverse Events EEG signal clarity was comparable to standard of care 10-20 scalp-based recordings Clinically relevant findings were identified in 88% of drug-resistant epilepsy patients, including patients with frequent unreported seizures Minder's unique bilateral recording capability revealed clinically relevant findings not possible with unilateral recordings in 23% of patients Commercial Outlook: Rohan Hoare, Epiminder's CEO, said, 'We are very pleased with the positive impact that Minder can have on the lives of people with epilepsy. Following the FDA authorization in April 2025, Epiminder will initiate a phased U.S. launch in Q3 2025, targeting major epilepsy centers.' Please visit Epilepsia for open access to the UMPIRE publication. Follow Epiminder on LinkedIn and explore for more information. About Minder Minder is a minimally invasive device for continuous monitoring of electrographic activity of the brain, providing epilepsy patients and their doctors with detailed data on brain activity over an extended period. Patients can wear the device as they go about their normal daily activities. Minder's long-term monitoring of patients outside of a controlled clinical environment provides data needed for better understanding and more effective treatment of underlying conditions, including determining the effectiveness of drug therapies and other potential interventions. About Epiminder Founded in 2017 by Professor Mark Cook together with the Bionics Institute, St Vincent's Hospital, the University of Melbourne and Cochlear Limited, Epiminder is a medical device and information solutions company focused on developing diagnostic and treatment tools for epilepsy and other seizure disorders where continuous monitoring is required. Epiminder is headquartered in Melbourne, Australia and has offices in the United States.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store